So I understand this, because I am going to be on this for the next 4 years, you are saying, given previous case law and the Bellmon Review, that you are prohibited from actively managing quality parameters of ALJs. Is that what your testimony is?
Coburn questions the ability to manage ALJ quality based on previous case law.
Share
More from Tom Coburn
If we really want to move forward, what we have to do is change the dynamic at the FDA.
the Constitution, actually, is the powerful tool with which to solve the problems of our country.
I want to thank Senator Lankford in his role as the Chairman of my Appropriations Subcommittee.
Other voices in this conversation
